Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure.
Nicolas ClementyBruno GarciaClémentine AndréArnaud BissonNazih BenhendaBertrand PierreAnne BernardLaurent FauchierEric PiverDominique BabutyPublished in: PloS one (2018)
Galectin-3 levels independently predict outcomes in patients with reduced left ventricular systolic function addressed for ablation of persistent AF, and may be of interest in defining the therapeutic strategy in this population.
Keyphrases
- heart failure
- left ventricular
- atrial fibrillation
- catheter ablation
- left atrial
- cardiac resynchronization therapy
- blood pressure
- hypertrophic cardiomyopathy
- aortic stenosis
- acute myocardial infarction
- mitral valve
- oral anticoagulants
- left atrial appendage
- direct oral anticoagulants
- adipose tissue
- type diabetes
- insulin resistance
- metabolic syndrome
- acute coronary syndrome
- weight loss
- skeletal muscle